Zhejiang Dayang Biotech Group Co (003017) — Working Capital to Net Assets Ratio
Zhejiang Dayang Biotech Group Co (003017) has a Working Capital to Net Assets ratio of 12.5% as of March 2026. Working capital of CN¥146.61 Million (current assets of CN¥797.84 Million minus current liabilities of CN¥651.23 Million) is measured against net assets of CN¥1.17 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Zhejiang Dayang Biotech Group Co leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhejiang Dayang Biotech Group Co Working Capital to Net Assets (2013–2025)
This chart shows how Zhejiang Dayang Biotech Group Co's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 12.5%, reflecting working capital of CN¥146.61 Million against net assets of CN¥1.17 Billion CNY. See 003017 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zhejiang Dayang Biotech Group Co (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Dayang Biotech Group Co from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 003017 market cap overview.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 12.2% | CN¥138.74 Million | CN¥1.14 Billion | CN¥771.31 Million | CN¥632.58 Million | ▲ +0.5 pp |
| 2024 | 11.7% | CN¥122.85 Million | CN¥1.05 Billion | CN¥690.55 Million | CN¥567.70 Million | ▼ -11.3 pp |
| 2023 | 22.9% | CN¥231.38 Million | CN¥1.01 Billion | CN¥661.63 Million | CN¥430.26 Million | ▼ -2.4 pp |
| 2022 | 25.4% | CN¥249.92 Million | CN¥985.05 Million | CN¥728.16 Million | CN¥478.24 Million | ▼ -17.6 pp |
| 2021 | 43.0% | CN¥425.53 Million | CN¥990.71 Million | CN¥742.70 Million | CN¥317.16 Million | ▼ -9.0 pp |
| 2020 | 52.0% | CN¥497.78 Million | CN¥958.13 Million | CN¥698.29 Million | CN¥200.51 Million | ▲ +24.9 pp |
| 2019 | 27.1% | CN¥134.95 Million | CN¥498.09 Million | CN¥265.59 Million | CN¥130.64 Million | ▼ -0.9 pp |
| 2018 | 27.9% | CN¥123.14 Million | CN¥440.62 Million | CN¥269.92 Million | CN¥146.77 Million | ▲ +10.2 pp |
| 2017 | 17.7% | CN¥59.91 Million | CN¥337.71 Million | CN¥223.79 Million | CN¥163.88 Million | ▲ +32.2 pp |
| 2016 | -14.5% | CN¥-33.18 Million | CN¥229.35 Million | CN¥193.87 Million | CN¥227.05 Million | ▲ +5.2 pp |
| 2015 | -19.7% | CN¥-41.33 Million | CN¥209.76 Million | CN¥207.79 Million | CN¥249.12 Million | ▲ +0.3 pp |
| 2014 | -20.0% | CN¥-39.30 Million | CN¥196.87 Million | CN¥227.13 Million | CN¥266.43 Million | ▼ -8.3 pp |
| 2013 | -11.7% | CN¥-21.85 Million | CN¥187.42 Million | CN¥232.08 Million | CN¥253.93 Million | — |